Serologic characterization of hGPA expressed on the surface of hGPA-Tg-mRBCs
| Source of RBCs . | RBC type . | mAb/specificity/isotype . | |||||
|---|---|---|---|---|---|---|---|
| 6A7/M/IgG1 . | N92/N/IgG2a . | NaM16-1B10/hGPA/IgM . | 10F7/hGPA/IgG1 . | NaM10-2H12/hGPA/IgG3 . | NaM26-3F4/hGPA/IgG1 . | ||
| Human no. 1 | M+N− | > 128 | 0 | 64 | 16 | 1600 | 64 |
| Human no. 2 | M−N+ | 0 | + | 64 | 16 | 1600 | 32 |
| Mouse no. 1 | hGPA-Tg | 128 | 0 | 64 | 64 | 1600 | 8 |
| Mouse no. 2 | hGPA-Tg | 128 | 0 | 64 | 128 | 1600 | 8 |
| Mouse no. 3 | hGPA-Tg | > 128 | 0 | 64 | 128 | 1600 | 8 |
| Mouse no. 4 | Wild-type | 0 | 0 | 0 | 0 | 0 | 0 |
| Source of RBCs . | RBC type . | mAb/specificity/isotype . | |||||
|---|---|---|---|---|---|---|---|
| 6A7/M/IgG1 . | N92/N/IgG2a . | NaM16-1B10/hGPA/IgM . | 10F7/hGPA/IgG1 . | NaM10-2H12/hGPA/IgG3 . | NaM26-3F4/hGPA/IgG1 . | ||
| Human no. 1 | M+N− | > 128 | 0 | 64 | 16 | 1600 | 64 |
| Human no. 2 | M−N+ | 0 | + | 64 | 16 | 1600 | 32 |
| Mouse no. 1 | hGPA-Tg | 128 | 0 | 64 | 64 | 1600 | 8 |
| Mouse no. 2 | hGPA-Tg | 128 | 0 | 64 | 128 | 1600 | 8 |
| Mouse no. 3 | hGPA-Tg | > 128 | 0 | 64 | 128 | 1600 | 8 |
| Mouse no. 4 | Wild-type | 0 | 0 | 0 | 0 | 0 | 0 |
A panel of mouse mAbs recognizing either a sialic acid-dependent M epitope on hGPA (ie, 6A7), a sialic-independent N epitope on hGPA (ie, N92), or peptide epitopes on both M- and N-type hGPA (ie, NaM16-1B10, 10F7, NaM10-2H12, and NaM26-3F4) was used to evaluate hGPA expression on hGPA-Tg-mRBCs. Human RBCs of defined MN type were positive controls. RBCs from a wild-type FVB/NJ mouse were used as a negative control. The inverse agglutination titers are provided in each case, except for the results of the N92 mAb with the RBCs obtained from human no. 2, in which strong agglutination was seen, but titers were not performed. As additional controls, wild-type and hGPA-Tg-mRBCs were agglutinated by a rabbit polyclonal anti–mRBC IgG antibody (not shown).